Tsuge S, et al: CHS in cannabis-restrictive countries Case Reports Juntendo Medical Journal 2026. 72(3), 332-335 Suspected Cannabinoid Hyperemesis Syndrome in a Traveler from a Cannabis-Legal Country: A Case Report from Japan Shiho TSUGE, Riki SAKURAI, Kenta KONDO, Katsuhiko KADOTA, Makoto HIKI, Shin WATANABE, Yutaka KONDO Department of Emergency and Critical Care Medicine, Juntendo University Hospital, Tokyo, Japan TEL: +81-3-3813-3111 〔Received FAX: +81-3-3814-5431 Feb. 5, 2026〕 〔Accepted E-mail: s.tsuge.hf@juntendo.ac.jp May. 8, 2026〕 Copyright © 2026 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ26-0010-CR 332 Juntendo Medical Journal 72(3), 2026 were contacted the day after arrival. His medical history included attention-deficit/hyperactivity disorder and depression, managed with selective serotonin reuptake inhibitors. He had no other significant medical history, with no history of sexu­ ally transmitted infections. There was no history of consuming raw or spoiled food, and no known exposure to infectious illness in his surroundings. Objective findings and diagnostic assessment At the ED, he had a Glasgow Coma Scale score of 15 (E4V5M6); however, he was markedly agitated, standing up on the examination bed and verbally assaulting medical staff. Other vital signs were stable: heart rate 76 beats/min, respiratory rate 16 breaths/min, blood pressure 105/87 mmHg, tempera­ ture 36.6℃, and oxygen saturation 99% on room air. No abnormalities were identified on examination of the head and neck, chest, extremities, or neurolog­ ical assessment. No injection marks were observed. Abdominal examination revealed diffuse tenderness without guarding, rebound tenderness, or abnormal bowel sounds. Laboratory findings are shown in Table 1. Venous blood gas analysis revealed respi­ ratory alkalosis, suggesting hyperventilation due to agitation. Blood tests revealed neutrophilic leuko­ cytosis, mildly elevated liver enzymes, and mildly elevated hemoglobin. Infectious etiology was not actively pursued given the absence of fever and negative C-reactive protein. Other parameters were within normal limits, and the observed abnormali­ ties were attributed to dehydration and persistent vomiting. Abdominal ultrasonography revealed no findings suggestive of organic disease. A computed tomography (CT) scan was not performed as the patient refused due to concerns about insurance costs. As no clear organic cause was identified to explain his agitation and aggression, drug intoxica­ tion was suspected. Upon further history-taking regarding substance use, he reported a history of chronic and regular cannabis use for several years, using cannabis two to four times per week, with his last use the day before his departure. Urine drug screening (SIGNIFYTM ER kit) was positive for cannabis (tetrahydrocannabinol [THC]). Following a thorough review of his history and clinical presen­ tation, CHS was suspected as the leading differen­ tial diagnosis, based on his history of chronic cannabis use, a positive urine drug screening for cannabis, and otherwise unexplained recurrent vomiting and abdominal pain. Treatment and clinical course In the ED, 1000mg of intravenous acetaminophen was administered initially, without success. Subse­ quently, 15mg of pentazocine and 25mg of hydroxy­ zine hydrochloride were administered to improve abdominal pain, vomiting, and agitation. As symp­ toms sufficiently improved, the patient was discharged from the ED on the same day. At discharge, he was advised to abstain from cannabis use and informed of the possibility of symptom recurrence. Although we do not know when he returned to Canada, no subsequent hospital visits have been documented to our knowledge. Table 1 Laboratory data on admission Parameter Patient value Reference range pH 7.6 pvO2 (mmHg) 28.8 pvCO2 (mmHg) 19.6 Bicarbonate (mmol/L) 19.2 Lactate (mmol/L) 3.3 Glucose (mg/dL) 147 White cell count (/μL) 15,700 3,900-9,700 Neutrophils (%) 89.1 37.9-76.8 Lymphocytes (%) 7.8 16.5-49.5 Hemoglobin (g/dL) 17.1 13.4-17.1 Total bilirubin (mg/dL) 1.2 0.4-1.2 AST (U/L) 45 5-37 ALT (U/L) 73 6-43 ALP (U/L) 69 38-113 LDH (U/L) 224 124-222 Amylase (U/L) 56 43-124 CK (U/L) 237 57-240 BUN (mg/dL) 17 9-21 Creatinine (mg/dL) 0.66 0.6-1.0 Sodium (mmol/L) 142 135-145 Potassium (mmol/L) 3.7 3.5-5 C-reactive protein (mg/dL) 0.18 -0.29 AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, LDH: Lactate dehydrogenase, CK: Creatine kinase, BUN: Blood urea nitrogen Reference ranges for venous blood gas parameters are not shown, as standardized reference ranges for venous samples were unavail­ able. 333 Tsuge S, et al: CHS in cannabis-restrictive countries Discussion We report a rare and instructive case of suspected CHS in a foreign patient, highlighting the unique diagnostic challenges associated with differing linguistic, cultural, and legal backgrounds. This report underscores the importance of considering CHS in EDs within cannabis-prohibited countries. CHS is a relatively new clinical entity first reported in Australia in 20044). Subsequently, the legalization of cannabis in the United States, Canada, and several other countries has led to a surge in reported cases and growing global awareness5). CHS predominantly affects individuals aged 18-35 years, with males comprising approximately 69% of cases1, 2, 6). The diagnosis of CHS is based on the Rome Ⅳ criteria, which require all three of the following to be fulfilled: (i) stereotypical episodic vomiting, (ii) onset following prolonged cannabis use, and (iii) resolution of symptoms with sustained cannabis cessation. These criteria must have been present for the preceding three months, with symptom onset occurring at least six months prior to diagnosis7). Compulsive hot bathing behavior is a recognized supportive feature with diagnostic value8). The clinical presentation of this case, featuring severe vomiting and abdominal pain in the setting of chronic cannabis use, is consistent with the hyperemetic phase of CHS. However, a definitive diagnosis could not be established. While chronic cannabis use exceeding one year was confirmed, prior similar episodes could not be verified, and symptom resolution following cessation could not be observed. Notably, in chronic cannabis users, THC metabolites may remain detectable in urine for several weeks following cessation9); therefore, the positive urine drug screen in this case does not necessarily confirm recent use and must be inter­ preted with caution. These findings illustrate the inherent difficulty of applying the Rome Ⅳ criteria in a single ED encounter, and the diagnosis remains that of suspected CHS. Several diagnostic challenges were encountered. Compulsive bathing behavior was not assessed due to insufficient clinical aware­ ness of CHS at the time of evaluation. Additionally, the patient did not initially disclose cannabis use, and the diagnosis was only considered after a posi­ tive urine drug screening for THC. These issues reflect the combined impact of linguistic and cultural 334 barriers and limited clinical recognition of CHS. For acute pharmacological management, dopa­ mine antagonists such as haloperidol and droperidol are recommended as first-line agents, with topical capsaicin as adjunctive therapy10-13). Conventional antiemetics such as ondansetron have demonstrated limited efficacy, and opioids should be avoided due to the risk of exacerbating symptoms and the potential for dependence1, 10, 13). The definitive treat­ ment is complete cannabis cessation, after which symptoms typically resolve within weeks to months. However, recurrence is common, as many patients resume use due to dependence or social factors, and therefore, psychosocial support is recommended to improve long-term outcomes14). Regarding treatment in this case, pentazocine and hydroxyzine were administered concurrently for severe pain and agitation. In light of current evidence, the use of pentazocine, an opioid, was suboptimal; haloperidol would have been a more appropriate first-line agent10, 13). Whether symptom improvement was attributable to hydroxyzine, pentazocine, or spontaneous resolution cannot be determined, and no evidence currently supports the use of hydroxyzine in CHS. In cannabis-prohibited countries, foreign patients may face significant psychological barriers to disclosing cannabis use, even when such use was legal in their home country, and language barriers further compound these difficulties. In such settings, early consideration of CHS as a differential diag­ nosis and systematic history-taking —including specific inquiry about bathing behavior— is essen­ tial for timely recognition. These challenges are not limited to individual clinicians but represent a broader structural issue for emergency healthcare systems in cannabis-prohibited countries. There are several limitations to this report. The single ED visit, incomplete acquisition of key diag­ nostic information, inability to perform advanced imaging, and unknown long-term outcomes precluded a definitive diagnosis and limited the generaliz­ ability of our findings. Conclusion While CHS remains rare in Japan owing to strict regulations, the increasing global mobility of trav­ elers necessitates that physicians in non-legalized countries maintain a high index of suspicion for this Juntendo Medical Journal 72(3), 2026 condition. Overcoming language barriers and low clinical awareness is essential for the timely recog­ nition of CHS. Even when long-term follow-up is impossible, providing a provisional diagnosis and education regarding cannabis cessation constitutes a vital medical intervention for international trav­ elers.